10:44 AM EDT, 04/08/2025 (MT Newswires) -- Sellas Life Sciences Group ( SLS ) said Tuesday that group three data showed that tambiciclib topped the benchmark for median overall survival in the ongoing phase 2 relapsed/refractory acute myeloid leukemia study.

The median overall survival for all patients in the group was 8.8 months and 8.9 months for patients with AML-myelodysplasia-related changes or AML-MRC, exceeding the historical benchmark of 2.5 months, the company said.

The overall response rate in all evaluable patients was 46% in all group three patients and 67% in AML-MRC patients, surpassing the targeted 20% ORR, the company added.

The company said phase 2 trial continues in expansion groups four and five.

Shares of Sellas Life Sciences ( SLS ) rose 5.8% in recent trading.

Price: 1.10, Change: +0.06, Percent Change: +5.77